Literature DB >> 24615465

[Castration-resistant prostate cancer (CRPC)].

W Loidl1, F Luger, A Roosen.   

Abstract

In merely a short period of time the comprehension of castration-resistant prostate cancer has evolved. It is now possible to clearly outline the exact definition and variance of the disease pattern. A wealth of new effective agents can be applied to extend the patient's life span and improve the quality of life. An understanding of the pharmacodynamics and side effects of each substance is of utmost importance for the practical application. In order to use these new medicines in a differentiated manner urologists require continuous education. The evaluation of response to treatment has yet to be satisfyingly verified. Molecular markers still need to be developed and evaluated.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24615465     DOI： 10.1007/s00120-013-3377-0

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  30 in total

1.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE.

Authors:  C Huggins
Journal:  Ann Surg       Date:  1942-06       Impact factor: 12.969

Review 2.  Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Authors:  Srikala S Sridhar; Stephen J Freedland; Martin E Gleave; Celestia Higano; Peter Mulders; Chris Parker; Oliver Sartor; Fred Saad
Journal:  Eur Urol       Date:  2013-08-11       Impact factor: 20.096

3.  Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

Authors:  Howard I Scher; Xiaoyu Jia; Kim Chi; Ronald de Wit; William R Berry; Peter Albers; Brian Henick; David Waterhouse; Dean J Ruether; Peter J Rosen; Anthony A Meluch; Luke T Nordquist; Peter M Venner; Axel Heidenreich; Luis Chu; Glenn Heller
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases.

Authors:  B Têtu; J Y Ro; A G Ayala; D E Johnson; C J Logothetis; N G Ordonez
Journal:  Cancer       Date:  1987-05-15       Impact factor: 6.860

5.  Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Authors:  David R Shaffer; Margaret A Leversha; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V Doyle; Leon W M M Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

6.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

7.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 9.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

10.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544
View more
  1 in total

1.  Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122.

Authors:  Xiaonan Cong; Yundong He; Haigang Wu; Dingxiang Wang; Yongrui Liu; Ting Shao; Mingyao Liu; Zhengfang Yi; Jianghua Zheng; Shihong Peng; Tao Ding
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.